Personal information

Other IDs

SciProfiles: 1551134

Countries

Canada

Activities

Collapse all

Employment (1)

Tom Baker Cancer Centre: Calgary, AB, CA

2019-07-01 to 2021-06-30 | Medical Oncology Fellow (Medical Oncology)
Employment
Source: Self-asserted source
Carla Pires Amaro

Education and qualifications (3)

Hospital Beneficência Portuguesa de São Paulo: Sao Paulo, SP, BR

2016-03-01 to 2019-02-28 | Medical Oncology Fellow (Medical Oncology)
Qualification
Source: Self-asserted source
Carla Pires Amaro

Hospital Santo Antonio: Salvador, Bahia, BR

2014-03-01 to 2016-02-28 | Internal Medicine Fellow (Internal Medicine)
Qualification
Source: Self-asserted source
Carla Pires Amaro

Universidade Federal da Bahia: Salvador, BA, BR

2008-03-01 to 2013-01-31 | Doctor, MD
Education
Source: Self-asserted source
Carla Pires Amaro

Professional activities (1)

American Society of Clinical Oncology: Alexandria, VA, US

Membership
Source: Self-asserted source
Carla Pires Amaro

Works (7)

Dosing, efficacy and safety of lenvatinb in the real‐world treatment of hepatocellular carcinoma: Results from a Canadian database

Liver Cancer International
2022-09 | Journal article
DOI: 10.1002/lci2.59
Contributors: Carla Pires Amaro; Michael J. Allen; Jennifer J. Knox; Erica S. Tsang; Howard J. Lim; Richard M. Lee‐Ying; Kelvin W. Chan; Jessica Qian; Brandon M. Meyers; Alia Thawer et al.
Source: check_circle
Crossref

Radiation Therapy With Cyclin-Dependent Kinase 4/6 Inhibitors: A Multi-institutional Safety and Toxicity Study

International Journal of Radiation Oncology*Biology*Physics
2022-07 | Journal article
DOI: 10.1016/j.ijrobp.2022.07.005
Part of ISSN: 0360-3016
Contributors: Carla Pires Amaro
Source: Self-asserted source
Carla Pires Amaro

First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta

Current Oncology
2021-06-18 | Journal article
DOI: 10.3390/curroncol28030209
Part of ISSN: 1718-7729
Contributors: Carla Pires Amaro
Source: Self-asserted source
Carla Pires Amaro

Metastatic pancreatic cancer with complete response to FOLFIRINOX treatment

BMJ Case Reports
2021-05 | Journal article
DOI: 10.1136/bcr-2020-238395
Part of ISSN: 1757-790X
Source: Self-asserted source
Carla Pires Amaro

Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond.

Current oncology (Toronto, Ont.)
2020-11-01 | Journal article
DOI: 10.3747/co.27.7103
PMID: 33343211
PMC: PMC7739522
Source: Self-asserted source
Carla Pires Amaro

Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database.

Cancer medicine
2020-06-11 | Journal article
DOI: 10.1002/cam4.3228
PMID: 32529797
PMC: PMC7367626
Source: Self-asserted source
Carla Pires Amaro
grade
Preferred source (of 2)‎

CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease

Therapeutic Advances in Medical Oncology
2018-01 | Journal article
DOI: 10.1177/1758835918818346
Part of ISSN: 1758-8359
Part of ISSN: 1758-8359
Source: Self-asserted source
Carla Pires Amaro
How many people are using ORCID?